Subtype characteristics and drug resistance analysis of newly reported patients with HIV/AIDS before antiviral treatment in Nanning,2020-2023

doi:10.19871/j.cnki.xfcrbzz.2024.05.002

Abstract

Abstract: Objective To analyze the prevalence of HIV-1 genotypes and the transmitted drug resistance in HIV/AIDS patients before antiviral treatment from 2020 to 2023 in Nanning City,provide a reference for the development of prevention and control strategies for newly reported HIV infections in the region. Method 374 whole blood specimens from newly confirmed non-ART HIV/AIDS patients in Guangxi from January 2020 to December 2023 were collected for HIV-1 drug resistance testing. After extracted nucleic acids were reverse transcribed, the HIV-1 pol region gene was amplified by nested PCR and sequenced by Sanger sequencing, and the sequence information was analyzed according to tools such as the Stanford University HIVdb Program Drug Resistance Database. Result A total of 346 samples were successfully sequenced. Among them 9 subtypes were detected, mainly CRF01_AE subtypes and B/C recombinant, accounting for 29.48% and 27.46%. The subtype distribution between males and females was significantly different, and the subtype distribution in different sex-transmitted infections was also significantly different（P<0.05）. The overall drug resistance rates of PDR was 8.09%(28/346) with 2.89% to NRTIs, 3.75% to NNRTIs, 1.73% to PIs, and 0.29% to INSTIs. The drug resistance mutation rate of genotypic subtypes was 22.83% (79/346), and the mutation rates of resistance sites for NRTIs, NNRTIs, PIs and INSTIs were 4.91%, 15.32%, 2.02% and 2.31%, respectively. Conclusion Newly reported patients with HIV infection/AIDS in Nanning City are mainly CRF01_AE subtype HIV-1 infections, meanwhile, the pre-ART resistance rate has reached a medium-high level, and INSTIs resistant strains have emerged. Surveillance of HIV-1 subtypes prevalence and the drug resistance monitoring of newly reported HIV-infected people before ART need to be strengthened.

Key words: Human immunodeficiency virus, Drug resistance before treatment, HIV-1 subtype, Drug resistance mutation

CLC Number:

Li Xuehua, Liu Jie, Huang Jinping, Lu Huan, Liu Xin, Qin Qiuzhen, Li Yangping, Ye Li, Li Yanjun. Subtype characteristics and drug resistance analysis of newly reported patients with HIV/AIDS before antiviral treatment in Nanning,2020-2023[J]. Electronic Journal of Emerging Infectious Diseases, 2024, 9(5): 8-13.

References

[1] 沈银忠, 卢洪洲, 陈耀凯, 等. 人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识[J/CD]. 新发传染病电子杂志, 2022, 7(1):73-87.
[2] DAT VQ, ANH NTL, NGHIA KV, et al.The prevalence of pre-treatment and acquired HIV drug resistance in Vietnam:a nationally representative survey, 2017-2018[J]. J Int AIDS Soc, 2022, 25(2):e25857.
[3] SHCHEMELEV AN, OSTANKOVA YV, VALUTITE DE, et al.Risk assessment of first-line treatment failure in untreated HIV patients in Northwestern Federal District of the Russian Federation[J]. Russian Journal of Infection and Immunity, 2023, 13(2):302-308.
[4] 许小珊, 黄荣叶, 陈欢欢, 等. 治疗前耐药对HIV感染者抗病毒治疗12个月病毒抑制影响[J]. 中国热带医学, 2022, 22(6):549-554.
[5] 沈平, 苏齐鉴, 黄毅毅, 等. 钦州市钦南区HIV-1原发性耐药及其影响因素的研究[J]. 中国热带医学, 2015, 15(10):1181-1185.
[6] 吴楠楠, 殷玥琪, 袁瑞, 等. 我国HIV亚型与耐药性Meta分析[J]. 中华流行病学杂志, 2016, 37(11):1546-1554.
[7] 吴亚松, 马烨. 中国艾滋病病毒耐药现状[J/CD]. 新发传染病电子杂志, 2019, 4(3):181-184.
[8] 梁焱铃, 冯毅, 邵一鸣. HIV-1 C亚型、CRF07_BC和CRF08_BC重组毒株的起源和分子流行病学研究进展[J]. 中国艾滋病性病, 2021, 27(5):549-552.
[9] LI Y, HAN Y, XIE J, et al.CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission[J]. AIDS, 2014, 28(4):521-530.
[10] 李剑军, 陈燕兰, 葛宪民, 等. 广西壮族自治区2020年新报告≥50岁男性HIV感染者的HIV-1基因亚型分布及其与首次CD4⁺T淋巴细胞的关联[J]. 中华疾病控制杂志, 2022, 26(12):1389-1394.
[11] 郑惠结, 徐理倩, 吴昊, 等. 广州市2008-2015年男男性行为者感染HIV-1的分子传播网络特征[J]. 中国艾滋病性病, 2020, 26(11):1169-1173.
[12] 龙海, 甘霖, 杨小燕, 等. 贵阳市266例新发现HIV/AIDS患者抗病毒治疗前HIV-1耐药及亚型特征[J]. 中国艾滋病性病, 2022, 28(12):1350-1354.
[13] 曹旭健, 曹静, 祁慧, 等. 湖南省HIV-1感染者原发性耐药现况调查[J]. 中国感染控制杂志, 2023, 22(4):451-456.
[14] 李莉, 安希钊, 粟斌, 等. 2019—2022年北京某院HIV-1新发感染者抗病毒治疗前耐药情况分析[J]. 现代医药卫生, 2024, 40(12):1990-1995.
[15] 乔瑞娟, 张林才, 冯毅, 等. 甘肃省部分地区2020-2021年新报告HIV/AIDS患者治前耐药及分子传播网络特征分析[J]. 中国艾滋病性病, 2023, 29(8):860-865.
[16] 方星, 张信辉, 邢辉, 等. 2018年贵州省南北部地区艾滋病感染者抗病毒治疗前HIV-1基因亚型和耐药情况研究[J]. 贵州医药, 2021, 45(9):1354-1356.
[17] 王小丽, 周健明, 金玉娟, 等. 深圳市龙岗区男男性接触者HIV感染者流行病学特征及原发性耐药分析[J]. 中华疾病控制杂志, 2021, 25(12):1441-1446.
[18] 欧阳金鸣. 我国CRF01_AE HIV-1毒株的基因型和表型耐药研究[D]. 北京:中国医科大学, 2022.
[19] 卢焕, 吴念宁, 欧汝志, 等. 广西桂南地区抗病毒治疗艾滋病患者耐药特征及影响因素分析[J]. 广东医学, 2022, 43(1):98-102.
[20] 方宁烨, 韦文翠, 李剑军, 等. 广西≥50岁男性新报告人类免疫缺陷病毒感染者的基因亚型及治疗前耐药分析[J]. 中国医学科学院学报, 2023, 45(3):399-404.
[21] MELIKIAN GL, RHEE S, VARGHESE V, et al.Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance:implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing[J]. J Antimicrob Chemother, 2014, 69(1):12-20.
[22] TSIANG M, JONES GS, GOLDSMITH J, et al.Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile[J]. Antimicrob Agents Chemother, 2016, 60(12):7086-7097.
[23] 王辉. 复方新药Biktarvy@在中国HIV抗病毒治疗中的临床价值[J/CD]. 新发传染病电子杂志, 2019, 4(2):85-90.
[24] 黄晓彤. 沈阳市新诊断HIV感染者整合酶抑制剂原发耐药研究[D]. 北京:中国医科大学, 2020.
[25] 宋畅, 周佳佳, 董敖渤, 等. 2018年我国部分省份抗病毒治疗前HIV-1整合酶抑制剂耐药流行情况[J]. 中国艾滋病性病, 2021, 27(4):348-351.